Skip to main content
Fig. 5 | Journal of Hematology & Oncology

Fig. 5

From: Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms

Fig. 5

NiPT triggers cell apoptosis and proteasome inhibition in cancer cells from CML patients. a NiPT decreases cell viability of CML patient cancer cells. CML cells from 12 CML patients were treated with NiPT at the indicated doses for 48 h, and cell viability was detected by the MTS assay. Mean ± SD (n = 3). b NiPT induces cell apoptosis in CML patient cancer cells. Cancer cells from CML patients were isolated and incubated with NiPT for 36 h, followed by detecting the Annexin V/PI positive cells by flow cytometry. Representative images are shown. c NiPT accumulates ubiquitinated proteins and IκB-α in CML cancer cells. Cancer cells from three CML patients were treated with NiPT for 6 h. The indicated proteins were analyzed using western blots. (#3, 5: imatinib-sensitive patients; #12: imatinib-resistant patient). d NiPT induces cleavage of PARP and caspase-3 or caspase-9, and downregulates Mcl-1 protein in patients’ cancer cells. Cells from CML patients were treated with NiPT, and the indicated proteins were detected with western blots (#5, 8: imatinib-sensitive patients; #11: imatinib-resistant patient)

Back to article page